Recent studies have shown that IL‐6 expression is upregulated in EGFR‐mutated NSCLC tumors, which mediates resistance to EGFR‐TKIs.[76] This was also observed in our transcriptomics and validation results, accompanied by enhanced phosphorylation of STAT3 downstream of IL‐6 in SHP099 treatment, which further expanded the indications for dual targeting of XIAP and SHP2. The gene discussed is IL6; the disease is non-small cell lung carcinoma.